Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Summary

This phase I trial studies the side effects and best dose of pomalidomide in treating patients with Waldenstrom macroglobulinemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Pomalidomide may stimulate the immune system in different ways and stop cancer cells from growing.

Timeline

Start

2010-10-06

Primary completion

2025-05-02

Completion

2025-05-02

Drugs

Indications